Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

计划入组 88 人 · 首次发布于 2019 年 8 月 20 日

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

计划入组 152 人 · 首次发布于 2003 年 7 月 4 日

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

计划入组 30 人 · 首次发布于 2024 年 2 月 12 日

Pirtobrutinib(Jaypirca)

C₂₂H₂₁F₄N₅O₃

FOX01 inhibitor program (mantle cell lymphoma)

anti-BCMA CAR T-cell therapy (refractory or relapsed multiple myeloma)

CARGO Therapeutics

United States

Tres-Or Resources Ltd

AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP

Australia

Bristol Myers Squibb Receives European Commission Approval for Breyanzi in Relapsed/Refractory Mantle Cell Lymphoma

LP-168, a Novel BTK Inhibitor, Shows Promise in Relapsed/Refractory Mantle Cell Lymphoma

Brexucabtagene Autoleucel Shows High Efficacy in BTK Inhibitor-Naive Mantle Cell Lymphoma